The proposed interaction of NAMPT and PD-L1 and their dual targeting by LZFPN-90 were explored, raising the possibility that the pharmacological blockade of NAMPT and simultaneous immune checkpoint blockade represent a promising strategy for cancer therapy. Here, CD274 is linked to cancer.